Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia-Reference-Cited by-同舟云学术

Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia

Published:2012-01-29 Issue:3 Volume:8 Page:277-284
ISSN:1552-4450
Container-title:Nature Chemical Biology
language:en
Short-container-title:Nat Chem Biol

Author:

Grembecka Jolanta,He Shihan,Shi Aibin,Purohit Trupta,Muntean Andrew G,Sorenson Roderick J,Showalter Hollis D,Murai Marcelo J,Belcher Amalia M,Hartley Thomas,Hess Jay L,Cierpicki Tomasz

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/nchembio.773.pdf

Reference42 articles.

1. Pui, C.H. et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 359, 1909–1915 (2002).

2. Liu, H., Cheng, E.H. & Hsieh, J.J. MLL fusions: pathways to leukemia. Cancer Biol. Ther. 8, 1204–1211 (2009).

3. Sorensen, P.H. et al. Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes. J. Clin. Invest. 93, 429–437 (1994).

4. Cox, M.C. et al. Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients. Am. J. Clin. Pathol. 122, 298–306 (2004).

5. Hess, J.L. MLL: a histone methyltransferase disrupted in leukemia. Trends Mol. Med. 10, 500–507 (2004).

Cited by 351 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vivo CRISPR screens identify a dual function of MEN1 in regulating tumor–microenvironment interactions;Nature Genetics;2024-09

2. Drug-resistant menin variants retain high binding affinity and interactions with MLL1;Journal of Biological Chemistry;2024-09

3. Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community;Leukemia;2024-08-23

4. Common Driver Mutations in AML: Biological Impact, Clinical Considerations, and Treatment Strategies;Cells;2024-08-21

5. Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101);Journal of Clinical Oncology;2024-08-09